This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
by Zacks Equity Research
Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
by Zacks Equity Research
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Company News for Sep 20, 2024
by Zacks Equity Research
Companies In The News Are: PGNY, EWTX, FDS, SCS.
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
by Zacks Equity Research
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
by Zacks Equity Research
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 310.1% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 327.9% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 224.3% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 157%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 156.9% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
by Zacks Equity Research
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).